Sharemaestro company-news research for AstraZeneca PLC (AZN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Measured evidence
Company news sentiment
AZN news sentiment
AstraZeneca PLC
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone66Neutral is 50
Constructive news tone
82/100 evidence confidence
100% direct company focus
17 current stories across 2 publishers
Current company news
Positive news being faded
Constructive news tone is drawn from 17 fresh independent stories, including 17 company-specific items across 2 publishers.
Latest source headline U.K. regulator reaffirms safety of childhood vaccination seekingalpha.com · 12 Aug 2026 13:13What supports the read
17 current stories are mapped specifically to AZN.
Cross-story agreement is 87/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
Constructive headlines are not being rewarded by price, which raises a rejection flag.
66/100
Weighted toneConstructive news tone
82/100
Evidence confidencehigh confidence
100%/100
Company focus17 direct stories
87/100
Evidence agreement13/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
15.91 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness65
recency-weighted evidenceAgreement87
cross-story consistencySource independence39
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive headlines are not being rewarded by price, which raises a rejection flag.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment-trend disagreement
News subjects
What is shaping the score
Earnings728 stories · 47%
Deals and strategy695 stories · 29%
Analyst action702 stories · 12%
Market update652 stories · 12%
Source mix
Where the evidence comes from
finance.yahoo.com7412 stories · 71%
seekingalpha.com605 stories · 29%
Recurring subjects
Subjects appearing most often
Earnings9Earnings Per Share6Pharma5Oncology5M A5Healthcare5Biotech4Guidance3Fourth Quarter3Fda Approval3
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#154Tone
seekingalpha.comDirect company coverage
U.K. regulator reaffirms safety of childhood vaccination
[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin
HealthcareRegulationSplitVaccines
- Published
- 12 Aug 2026 13:13
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#273Tone
finance.yahoo.comDirect company coverage
How AstraZeneca’s $400bn deal unravelled
One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
- Published
- 12 Aug 2026 04:00
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#370Tone
finance.yahoo.comDirect company coverage
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti
M AOncologyPatent ExpiryPharmaSplit
- Published
- 11 Aug 2026 19:34
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#473Tone
finance.yahoo.comDirect company coverage
Do Options Traders Know Something About AstraZeneca Stock We Don't?
Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho
BiotechImplied VolatilityOptions Trading
- Published
- 11 Aug 2026 14:11
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#574Tone
finance.yahoo.comDirect company coverage
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W
EarningsEarnings Per ShareOncologyPharmaRegulationTrials
- Published
- 11 Aug 2026 14:04
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#680Tone
finance.yahoo.comDirect company coverage
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue
AcquisitionsEarningsOncologyPatent ExpirationPharmaceuticalsRevenue Growth
- Published
- 11 Aug 2026 13:48
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#773Tone
seekingalpha.comDirect company coverage
Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves
Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent
EarningsFinancialsHealthcareRevenue Growth
- Published
- 11 Aug 2026 13:36
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#876Tone
finance.yahoo.comDirect company coverage
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m
BiotechEarningsFree Cash FlowGuidanceM AOperating Income
- Published
- 11 Aug 2026 13:20
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#984Tone
finance.yahoo.comDirect company coverage
Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals
During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see
EarningsEarnings Per ShareEarnings ReportFinancial ResultsFinancialsFourth Quarter
- Published
- 11 Aug 2026 05:43
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1084Tone
finance.yahoo.comDirect company coverage
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi
Balance SheetClinical TrialsDividendsEarningsEarnings GrowthEarnings Per Share
- Published
- 10 Aug 2026 23:44
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1154Tone
finance.yahoo.comDirect company coverage
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a
Balance SheetBiotechFda ApprovalFourth QuarterHealthcareM A
- Published
- 10 Aug 2026 18:07
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1268Tone
finance.yahoo.comDirect company coverage
Zimmer Biomet Q2 Earnings Call Highlights
Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness—especially in China—offsetting U.S. gains. Zimmer Biomet raised
EarningsEarnings Per ShareFree Cash FlowGrowth RateGuidanceHealthcare
- Published
- 09 Aug 2026 18:03
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1343Tone
seekingalpha.comDirect company coverage
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE
Consensus EstimateEarningsEarnings Per ShareGuidanceHealthcareM A
- Published
- 09 Aug 2026 13:05
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1434Tone
seekingalpha.comDirect company coverage
SA Asks: What's the outlook for Big Pharma M&A?
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth
BiotechFda ApprovalM&aM AOncologyPharma
- Published
- 08 Aug 2026 19:28
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1585Tone
seekingalpha.comDirect company coverage
Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets
[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a
AIConsensus EstimateEarningsEarnings Per ShareEarnings ReportFourth Quarter
- Published
- 08 Aug 2026 17:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1669Tone
finance.yahoo.comDirect company coverage
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too
Clinical TrialsOncologyPartnershipPharmaPrecision MedicineShare Price
- Published
- 08 Aug 2026 15:12
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1765Tone
finance.yahoo.comDirect company coverage
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs
Earnings EstimateFda ApprovalIntrinsic ValuePharmaPrice TargetPrice Target
- Published
- 07 Aug 2026 19:30
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
AZN news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
06
2026
MT NewswiresArchivedNeutral tone
AstraZeneca, Jaguar Land Rover Gain Access to UK's Fast-Track Visa
- Published
- 6 Aug 2026 03:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
03
2026
GuruFocus.comArchivedNeutral tone
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks
- Published
- 3 Aug 2026 22:07
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
Seeking AlphaArchivedNeutral tone
AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)
- Published
- 2 Aug 2026 21:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
Seeking AlphaArchivedNeutral tone
AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer
- Published
- 2 Aug 2026 14:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Seeking AlphaArchivedNeutral tone
Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)
- Published
- 31 Jul 2026 04:50
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
Argus ResearchArchivedNeutral tone
Analyst Report: AstraZeneca PLC
- Published
- 30 Jul 2026 04:30
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
Market sourceArchivedNeutral tone
AstraZeneca PLC (AZN) Stock Forecasts
- Published
- 28 Jul 2026 08:47
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
27
2026
GuruFocus.comArchivedNeutral tone
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
- Published
- 27 Jul 2026 22:00
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
27
2026
Ad-hoc-news.deArchivedNeutral tone
AstraZeneca stock trades steadily as oncology and cardiovascular growth underpin recent earnings
- Published
- 27 Jul 2026 15:22
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
GuruFocusArchivedNeutral tone
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance
- Published
- 23 Jul 2026 14:36
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
The Wall Street JournalArchivedNeutral tone
AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
- Published
- 23 Jul 2026 11:30
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
GuruFocusArchivedNeutral tone
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula
- Published
- 22 Jul 2026 03:30
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
17
2026
CryptoSlateArchivedNeutral tone
AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume
- Published
- 17 Jul 2026 11:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
Market sourceArchivedNeutral tone
AstraZeneca (LSE:AZN) Stock Could Trade At A 46% Discount After Wainua Setback
- Published
- 15 Jul 2026 12:11
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
Pharmaceutical TechnologyArchivedNeutral tone
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
- Published
- 15 Jul 2026 05:40
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
14
2026
Business WireArchivedNeutral tone
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
- Published
- 14 Jul 2026 03:40
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
12
2026
thestreet.comArchivedNeutral tone
AstraZeneca erases billions after sobering reveal
- Published
- 12 Jul 2026 10:31
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
Simply Wall St.ArchivedNeutral tone
AstraZeneca (LSE:AZN) Misses Key Wainua Trial Goal Beyond Oncology
- Published
- 10 Jul 2026 03:50
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
GuruFocusArchivedNeutral tone
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Te
- Published
- 9 Jul 2026 22:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
Stock TitanArchivedNeutral tone
AstraZeneca (AZN) officer receives share grant via incentive plan
- Published
- 9 Jul 2026 04:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
Seeking AlphaArchivedNeutral tone
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation - Slideshow (NYSE:AZN) 2026-07-06
- Published
- 7 Jul 2026 08:47
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
TradingKeyArchivedPositive tone
AstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?
- Published
- 6 Jul 2026 22:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
Market sourceArchivedNeutral tone
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance
- Published
- 6 Jul 2026 10:40
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
05
2026
The Twelfth MagpieArchivedNeutral tone
AstraZeneca share price edges higher on Enhertu drug gains cancer treatment approval. What are analysts forecasting?
- Published
- 5 Jul 2026 16:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
04
2026
simplywall.stArchivedNeutral tone
AstraZeneca (LSE:AZN) Stock May Be 37% Undervalued Despite Lung Cancer Trial News
- Published
- 4 Jul 2026 03:52
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
Stock TitanArchivedNeutral tone
Abbisko teams with AstraZeneca on lung cancer trial after China IND clearance
- Published
- 2 Jul 2026 03:40
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
ScripArchivedPositive tone
AstraZeneca Details Bone Health Data For Strensiq Successor
- Published
- 1 Jul 2026 05:48
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
GuruFocusArchivedPositive tone
AstraZeneca (AZN) Faces Competition from Anthropic's New AI in P
- Published
- 1 Jul 2026 04:59
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
ZacksArchivedPositive tone
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
- Published
- 30 Jun 2026 04:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
29
2026
simplywall.stArchivedPositive tone
AstraZeneca Stock And 2 UK Shares Where Cash Flow May Matter Most
- Published
- 29 Jun 2026 15:53
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.